677 related articles for article (PubMed ID: 33324348)
1. Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides.
Kořínková L; Pražienková V; Černá L; Karnošová A; Železná B; Kuneš J; Maletínská L
Front Endocrinol (Lausanne); 2020; 11():597583. PubMed ID: 33324348
[TBL] [Abstract][Full Text] [Related]
2. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
3. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
Chen Y; Xu YN; Ye CY; Feng WB; Zhou QT; Yang DH; Wang MW
Acta Pharmacol Sin; 2022 May; 43(5):1156-1166. PubMed ID: 34934197
[TBL] [Abstract][Full Text] [Related]
6. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.
Zhou D; Chen YW; Zhao ZH; Yang RX; Xin FZ; Liu XL; Pan Q; Zhou H; Fan JG
Exp Mol Med; 2018 Dec; 50(12):1-12. PubMed ID: 30510243
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective.
Yadav P; Khurana A; Bhatti JS; Weiskirchen R; Navik U
Pharmacol Res; 2022 Oct; 184():106426. PubMed ID: 36075510
[TBL] [Abstract][Full Text] [Related]
8. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
[TBL] [Abstract][Full Text] [Related]
9. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
10. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Budd J; Cusi K
Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
[TBL] [Abstract][Full Text] [Related]
11. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
Finn PD; Rodriguez D; Kohler J; Jiang Z; Wan S; Blanco E; King AJ; Chen T; Bell N; Dragoli D; Jacobs JW; Jain R; Leadbetter M; Siegel M; Carreras CW; Koo-McCoy S; Shaw K; Le C; Vanegas S; Hsu IH; Kozuka K; Okamoto K; Caldwell JS; Lewis JG
Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G412-G424. PubMed ID: 30605011
[TBL] [Abstract][Full Text] [Related]
12. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
13. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Bifari F; Manfrini R; Dei Cas M; Berra C; Siano M; Zuin M; Paroni R; Folli F
Pharmacol Res; 2018 Nov; 137():219-229. PubMed ID: 30359962
[TBL] [Abstract][Full Text] [Related]
14. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
15. Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease.
Alvares D; Hoffman S; Stankovic B; Adeli K
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Mar; 1864(3):326-334. PubMed ID: 30578967
[TBL] [Abstract][Full Text] [Related]
16. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
17. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
[TBL] [Abstract][Full Text] [Related]
18. Glucagon Like Peptide-1 Receptor Agonists Alter Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model.
Fang T; Huang S; Chen Y; Chen Z; Chen J; Hu W
Exp Clin Endocrinol Diabetes; 2021 Sep; 129(9):625-633. PubMed ID: 32961563
[TBL] [Abstract][Full Text] [Related]
19. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.
Dhir G; Cusi K
J Investig Med; 2018 Jan; 66(1):7-10. PubMed ID: 28918389
[TBL] [Abstract][Full Text] [Related]
20. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Stein LL; Dong MH; Loomba R
Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
